A Phase 3 interventional study of torcetrapib/atorvastatin and atorvastatin in Coronary Disease, Coronary Arteriosclerosis and Hyperlipidemia, sponsored by Pfizer. Completed at 147 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-12-10.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing atorvastatin in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Coronary Artery Disease.
Among the 33 studies testing atorvastatin in Coronary Artery Disease, this one is the 2nd largest by enrollment, is one of 5 that started in 2003, is one of 8 in phase 3, and was the 1st registered.
4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 33 studies testing atorvastatin in Coronary Artery Disease is open now, in 1 country. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,100 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 120 across the 33 interventional studies. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 33 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing atorvastatin in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease
For additional information please call: 1-800-718-1021
4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
This study's enrollment of 1,100 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronary Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug pages: Torcetrapib · Atorvastatin
Change coronary artery atheroma volume as measured by intravascular ultrasound.
Changes in levels of lipids and other biomarkers.
Showing the first 100 of 147 sites across 6 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2003 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Torcetrapib · Atorvastatin